Zymeworks
ZYME

Zymeworks (ZYME) analyst forecast and price target

Recent analyst ratings

FirmActionRatingPrice targetDate
Truist SecuritiesMaintainedBuy$34.00 from $32.00Oct 7, 2026
CitigroupMaintainedBuy$39.00 from $38.00Sep 29, 2026
Wolfe ResearchInitiated CoverageOutperform—Sep 17, 2026
JP MorganMaintainedOverweight$33.00 from $31.00Sep 3, 2026
HC Wainwright & Co.MaintainedBuy$55.00 from $51.00Aug 26, 2026
CitigroupMaintainedBuy$38.00 from $37.00Aug 26, 2026
CitizensMaintainedMarket Outperform$32.00Aug 26, 2026
B. Riley SecuritiesMaintainedBuy$44.00 from $40.00Aug 10, 2026
Truist SecuritiesMaintainedBuy$32.00 from $31.00Aug 7, 2026
Wells FargoMaintainedOverweight$40.00 from $37.00Aug 7, 2026
HC Wainwright & Co.MaintainedBuy$51.00 from $46.00Aug 5, 2026
Truist SecuritiesMaintainedBuy$31.00 from $28.00Jul 7, 2026
Wells FargoMaintainedOverweight$37.00 from $34.00Jun 30, 2026
HC Wainwright & Co.MaintainedBuy$46.00Jun 3, 2026
Wells FargoMaintainedOverweight$34.00 from $33.00May 8, 2026
Evercore ISI GroupMaintainedOutperform$48.00 from $33.00Mar 9, 2026
HC Wainwright & Co.MaintainedBuy$46.00 from $32.00Mar 6, 2026
Leerink PartnersMaintainedOutperform$58.00 from $52.00Mar 3, 2026
StifelMaintainedBuy$47.00 from $40.00Mar 3, 2026
Truist SecuritiesInitiated CoverageBuy$40.00Dec 17, 2025

Frequently asked questions

  • What is the latest analyst rating on ZYME?

    On Oct 7, 2026, Truist Securities maintained Zymeworks at Buy with a price target of $34.00.

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.